Lilly says Phase 3b TOGETHER-PsO data show broader biomarker shifts with Taltz plus Zepbound
LLY•Eli Lilly disclosed exploratory Phase 3b TOGETHER-PsO findings showing broader biomarker changes with Taltz plus Zepbound than with Taltz alone. The shifts began early and aligned with improved skin clearance and meaningful weight loss.
1. Biomarker findings
Eli Lilly disclosed new exploratory biomarker findings from its Phase 3b TOGETHER-PsO trial at Fall Clinical 2026. Taltz plus Zepbound showed broader biological changes than Taltz alone, beginning early in treatment; the shifts aligned with improved skin clearance and meaningful weight loss. Longer-term effects are being tracked through Week 52.
